Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data

Fineline Cube Aug 23, 2023

Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing...

Policy / Regulatory

Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance

Fineline Cube Aug 23, 2023

The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...

Company Deals

Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies

Fineline Cube Aug 23, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics....

Company Drug

European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma

Fineline Cube Aug 23, 2023

The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib Files for New Indication with China’s NMPA

Fineline Cube Aug 23, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the National Medical Products...

Company Drug

Kintor Pharmaceutical Completes Enrollment in Phase II Study of GT20029 for Androgenetic Alopecia

Fineline Cube Aug 23, 2023

China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a...

Company Drug

Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment

Fineline Cube Aug 23, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration...

Company Drug

Novatim’s KQ-2003 and KY-0118 Advance with Clinical Trial Approvals in China

Fineline Cube Aug 22, 2023

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial...

Company Drug

Sichuan Huiyu Pharmaceutical’s Plerixafor Gains Marketing Approval from Italian Medicines Agency

Fineline Cube Aug 22, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Epione Navigation System

Fineline Cube Aug 22, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received market approval from...

Company Deals

Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services

Fineline Cube Aug 22, 2023

China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to...

Company Deals

Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices

Fineline Cube Aug 22, 2023

Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products,...

Company Drug

Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study

Fineline Cube Aug 22, 2023

China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...

Company Deals

CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D

Fineline Cube Aug 22, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...

Company Drug

Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau

Fineline Cube Aug 22, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...

Company Medical Device

magAssist Receives FDA Breakthrough Device Designation for NyokAssist VAD

Fineline Cube Aug 22, 2023

magAssist, a firm based in Suzhou, China, has announced that it has received breakthrough device...

Company Drug

Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS

Fineline Cube Aug 22, 2023

Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...

Company

RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results

Fineline Cube Aug 22, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...

Company Drug

Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA

Fineline Cube Aug 22, 2023

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed...

Company

Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion

Fineline Cube Aug 22, 2023

China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...

Posts pagination

1 … 481 482 483 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.